NSCLC/MTT Episode 2 - Biomarker Testing: Shaping Personalized Medicine

Estimated Time
0.25 hr

Release Date
Nov 22, 2022

Expiration Date
Mar 31, 2024

For non-small cell lung cancer (NSCLC), the rates of 5-year survival have improved significantly over the past 10 years with improved early detection methods and the approval of highly effective targeted therapies. With an expansion of the treatment arsenal, it is up to clinicians to decipher the latest guideline recommendations and apply evolving clinical evidence to ensure optimal treatment selection and patient education. Join us for the second episode of the 4-part educational initiative Biomarker-based Therapy for NSCLC:  Improving Collaboration, Communication, and Care in which our expert faculty explore the implications of test results for prognosis and discuss methods to empower patients to engage in their care.


Accreditation and Disclosure Information

This CE activity is intended for oncology nurses and nurse practitioners who provide care for individuals with non-small cell lung cancer (NSCLC).

After completing this CE activity, the participant should be better able to:
  • Evaluate the implications of test results for prognosis, treatment selection, and patient education

Joint Accreditation with Commendation logo

In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 0.25 contact hour and 0.25 contact hour in the area of pharmacology.
The activity is supported by educational funding provided by Amgen and by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.  To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Tajuana Bradley, MSN, APRN-BC
Georgia Cancer Specialists
Gwinnett and Cumming
Affiliated with Northside Hospital Cancer Institute
Atlanta, GA
Speaker’s Bureau: ADC Therapeutics, Astra Zeneca, Bristol Myers Squibb, Coherus BioSciences, G1 Therapuetics, Puma Biotechnology, SeaGen
Blanca Ledezma, MSN, NP - AOCNP
Nurse Practitioner
UCLA Hematology - Oncology
Santa Monica, California
Speaker’s Bureau:  Amgen, AstraZeneca, Eisai, Helsinn, Lilly
Rasheda Persinger, MSN, AGNP-C, AOCNP
Medical Oncology Lead NP
Sidney Kimmel Cancer Center
Sibley Memorial Hospital Johns Hopkins
Washington DC
Advisory Board/Consultant: Pfizer
Speaker’s Bureau: AstraZeneca, Guardant Health
Saeed Sadeghi, MD, FACP
Clinical Professor of Medicine
David Geffen School of Medicine at UCLA 
Los Angeles, CA 
Speaker’s Bureau: AstraZeneca
All of the relevant financial relationships of individuals for this activity have been mitigated.
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with
recommendations of other authorities.
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact Nicole Dane via email at ndane@mlieducation.org.
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters,
Copyright © 2022 Medical Learning Institute, Inc. All Rights Reserved.